Tyra Biosciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Tyra Biosciences sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials 5 currently recruiting early-phase tilt upper quartile by trial count

Tyra Biosciences: 6 sponsored US clinical trials, 5 recruiting.

Tyra Biosciences sponsors 6 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is FGFR3 Gene Mutation, with 3 trials.

Upper-quartile sponsor footprint

Tyra Biosciences sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

6 total, page 1 of 1

RECRUITING Phase 2

Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

NCT07265947
RECRUITING Phase 2

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06995677
RECRUITING Phase 1

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

NCT06915753
RECRUITING Phase 2

A Study of TYRA-300 in Children With Achondroplasia: BEACH301

NCT06842355
RECRUITING Phase 1

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

NCT06160752
ACTIVE NOT RECRUITING Phase 1

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

NCT05544552

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3

Therapeutic Areas

FGFR3 Gene Mutation 3
FGFR3 Gene Alteration 3
FGFR Gene Alterations 2
FGFR Gene Amplification 2
Solid Tumor, Adult 2
Solid Tumor 2
Metastatic Cholangiocarcinoma 1
Locally Advanced Cholangiocarcinoma 1
FGFR3 Gene Fusions 1
Low-grade NMIBC 1

What is open in the Tyra Biosciences pipeline

5 recruiting of 6 indexed (83% open).

Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: FGFR3 Gene Mutation (3 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Tyra Biosciences: open-pipeline peers nationwide

Peers matched on 6 registered trials and 83% open enrollment, not the therapeutic-area sidebar.

Tyra Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 5.566.577.5 0%20%40%60%80%100% Total trials Recruiting share Tyra Biosciences23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan BranchCentessa Pharmaceuticals (UK) LimitedMeyer Children's Hospital IRCCSSystImmuneJohnson & Johnson Enterprise Innovation
Tyra Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Tyra Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 trials (± recruiting share)

Sponsors near 83% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Tyra Biosciences page

6 registered trials is a research-attention snapshot, not an endorsement of Tyra Biosciences or any single study.

  • 5 of Tyra Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • FGFR3 Gene Mutation is the condition Tyra Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See FGFR3 Gene Mutation trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Tyra Biosciences pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.